Liver Fibrosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Nucleoside Analog is the fastest growing sector, North America is the largest market

The global market for liver fibrosis drugs is projected to expand significantly, rising from USD 19.12 billion in 2025 to USD 33.91 billion by 2031, demonstrating a robust Compound Annual Growth Rate (CAGR) of 10.02%. This market comprises therapeutic agents designed to halt, slow, or reverse the abnormal buildup of extracellular matrix proteins in the liver, a condition often stemming from chronic liver damage. Key factors driving this growth include the increasing worldwide occurrence of chronic liver diseases, notably metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD).

Further bolstering demand are global demographic shifts, specifically an aging populace and escalating obesity rates, which fundamentally contribute to liver injury. The substantial patient base requiring effective treatments is evident, with nearly 100 million Americans affected by liver disease in 2024, as reported by the American Liver Foundation.

Market Drivers

The primary driver for the liver fibrosis drugs market's growth is the rising global incidence of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis. This chronic condition, strongly linked to increasing rates of obesity and type 2 diabetes, generates a critical need for treatments that can halt liver scarring before it advances to irreversible cirrhosis. The significant patient population highlights the urgent demand for effective interventions, as MASH has evolved from a silent issue into a global healthcare priority. For instance, approximately 5% of US adults are affected by MASH, as per Novo Nordisk in August 2025, confirming a vast potential market for new pharmacological treatments.

Concurrently, robust late-stage clinical pipelines and increasing R&D investments are revitalizing the market, finally producing significant efficacy data after prolonged development hurdles. Pharmaceutical firms are successfully progressing advanced candidates, including FGF21 analogs and GLP-1 receptor agonists, which show promise not only in addressing metabolic dysfunction but also in directly reversing existing fibrosis. This clinical advancement is illustrated by trial results, such as Akero Therapeutics' January 2025 report from the Phase 2b SYMMETRY Study, where 39% of patients on 50mg efruxifermin experienced cirrhosis reversal without disease worsening. The commercial viability of these scientific breakthroughs is already apparent, with Madrigal Pharmaceuticals reporting full-year 2024 net sales of $180.1 million in 2025 for its recently approved therapy, affirming the considerable revenue potential of successful anti-fibrotic treatments.

Market Challenges

A major impediment to the growth of the liver fibrosis drugs market is the inherent complexity of clinical development and regulatory approval processes. Regulatory agencies frequently mandate evidence of histological improvement, requiring invasive liver biopsies during clinical trials. This stipulation significantly hinders patient recruitment and retention due to the procedure's invasive nature, leading to reluctance among participants and higher dropout rates. As a result, pharmaceutical companies encounter prolonged study durations and increased research expenses, thereby decelerating the progression of new therapies through the development pipeline.

Moreover, the intricate underlying mechanisms of liver fibrosis contribute to a high incidence of late-stage clinical trial failures, creating a substantial void between the pressing medical need and the availability of approved treatments. This bottleneck prevents the market from adequately addressing a massive and expanding patient population; for instance, the Global Liver Institute estimated that metabolic dysfunction-associated steatotic liver disease affected around 30 percent of the global adult population in 2024. The inability to rapidly validate and commercialize drugs for such a large demographic directly constrains revenue generation and market expansion.

Market Trends

The development landscape is being transformed by the incorporation of non-invasive biomarkers as clinical endpoints, effectively resolving the major hurdle posed by the reliance on invasive liver biopsies. Regulatory authorities and drug developers are increasingly validating imaging and circulating biomarkers as surrogate endpoints, which simplifies patient recruitment and enables real-time assessment of treatment effectiveness.

This evolution permits the measurement of liver stiffness and fibrosis reduction without the risks linked to histological sampling, thereby directly accelerating the validation of new compounds. A significant regulatory step affirming this approach occurred in August 2025, when the FDA indicated its acceptance of liver stiffness measured by transient elastography as a reasonably likely surrogate endpoint for clinical trials, as reported by Fierce Biotech. This increased regulatory adaptability is anticipated to substantially shorten study durations and mitigate the high failure rates historically associated with fibrosis drug development.

Concurrently, the application of artificial intelligence (AI) in drug discovery is fundamentally reshaping the pace and accuracy with which anti-fibrotic candidates are identified and advanced. By employing deep learning algorithms to analyze extensive omics datasets, companies can now predict novel therapeutic targets and optimize molecular structures with unmatched efficiency, bypassing years of conventional trial-and-error.

This technological integration is proving vital for de-risking early-stage research and expediting the transition of compounds into clinical stages, thereby reducing innovation costs. The impact of this efficiency was underscored by Insilico Medicine's December 2025 press release, noting that its AI-driven platform facilitated the completion of the early discovery phase for its primary fibrosis candidate in just 18 months. These advancements highlight the crucial role of computational biology in bringing effective treatments to market more swiftly.

Key Market Players

• Gilead Sciences Inc
• Merck & Co Inc
• Bristol-Myers Squibb Co
• Johnson & Johnson Services, Inc.
• Novartis AG
• Vertex Pharmaceuticals Inc
• Pfizer Inc
• FibroGen Inc
• Pharmaxis Ltd

Report Scope

In this report, the Global Liver Fibrosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Liver Fibrosis Drugs Market, by Drug Class:

• Interferon Therapy
• Maloti Lipid
• Nucleoside Analog

Liver Fibrosis Drugs Market, by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Liver Fibrosis Drugs Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Liver Fibrosis Drugs Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.